BioCentury
ARTICLE | Discovery & Translation

Daley lab’s iPSC-derived T cell differentiation method; plus Harbour’s CTLA-4 antibody and more

BioCentury’s roundup of translational news

August 5, 2022 11:12 PM UTC

Researchers at Boston Children's Hospital including George Daley showed in Cell Stem Cell repressing the histone methyltransferase EZH1 promoted in vitro differentiation and maturation of T cells from iPSCs that display a molecular signature closely resembling mature TCRαβ T cells found in adult blood. The cells, derived in a stroma-free, serum-free system, were transduced with an anti-CD19 CAR and elicited stronger antitumor effects compared with iPSC-derived T cells without EZH1 knockdown in a xenograft mouse model of diffuse large B cell lymphoma.

Cell and gene therapy accelerator ElevateBio LLC announced Thursday that it formed a new company to develop allogeneic immune cell therapies based on the differentiation method to produce “EZ-T cells.” It is the first company to emerge from a five-year collaboration between Boston Children’s Hospital and ElevateBio. “Activated EZ-T cells give rise to high levels of memory T cells, which promotes T cell longevity and may be essential for durable remissions in cancer patients,” ElevateBio said in a statement...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article